NR3C2 and atrial fibrillation: These include negative therapeutic interactions, particularly the underuse or misuse of anticoagulation and beta-blockers, as well as challenges with rhythm control therapies such as amiodarone and propafenone, which carry pulmonary side effects, or of other agents such as mineralocorticoid receptor antagonists (MRAs), which have been shown to reduce the risk of atrial fibrillation but may be selectively underused due to side effects, drug interactions, or other complexities [8,9,33,47,48,49,50,51,52,53,54,55].